News | March 29, 2025
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
USFDA inspection at Alembic Pharma's Bioequivalence facility
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Subscribe To Our Newsletter & Stay Updated
